Results of a clinical trial examining the use of intralesional rituximab for the treatment of mucosa-associated lymphoid tissue (MALT) lymphoma.
Home / Resource Library / Treatment of MALT lymphoma of the conjunctiva with intralesional rituximab supplemented with autologous serum